Navigation Links
Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/5/2010

s from the September 2010 financing, was approximately $37.6 million.
  • For 2010, management anticipates total operating expenses will be $3 to $5 million less than those reported for 2009, which were approximately $72 million. Excluding the proceeds from the financing, the company continues to expect a net cash burn of $40 to $45 million for the year 2010.

  • Upcoming Corporate PresentationHalozyme representatives are scheduled to present at the following investor conference:

  • Lazard Capital Markets 7th Annual Healthcare Conference, November 17, 2010, 8:30 a.m. EST, New York City

  • To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. The replay will be available for 90 days after the event.

    Conference CallHalozyme management will host a conference call and webcast on November 5, 2010 to discuss these topics beginning at 8:00 a.m. PDT (11:00 a.m. EDT). To participate via telephone, please call 877.407.8037 for domestic callers or 201.689.8037 for international callers. A telephone replay will be available beginning shortly after the end of the call by dialing 877.660.6853 from the U.S. or 201.612.7415 for international callers and using account # 367 and replay ID # 359750. The conference call will be broadcast live over the Internet at www.halozyme.com and the replay will be available on the company's Web site for seven days.

    About Halozyme TherapeuticsHalozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extra
    '/>"/>

    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
    3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... 17, 2014 The global consumption of squalene / ... is a natural skin-identical chemical that finds applications in various ... supplements, pharmaceuticals, and in other applications like high grade lubrication, ... a few major players and is regionally segregated. Sophim ( ... Oil Co. Ltd. ( Japan ), SeaDragon Marine ...
    (Date:9/17/2014)... 2014  MiMedx Group, Inc. (NASDAQ: ... of patent protected regenerative biomaterials and bioimplants processed ... another peer-reviewed clinical study.    The ... Controlled Clinical Trial Evaluating the Use of ... Multi-layer Compression Therapy vs. Multi-layer Compression Therapy Alone ...
    (Date:9/17/2014)... Terracon Corporation has announced the introduction of ... This addition to the company’s industry-leading line of ... and available in 125 or 250 gallon capacities. ... weeks or less. , The new pre-engineered TerraPure tank ... existing TerraPure tank line – plus quick turnaround. ...
    (Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
    Breaking Biology Technology:Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4
    ... Tiny chemical particles emitted by diesel exhaust fumes could raise ... have found that ultrafine particles produced when diesel burns are ... blood clots forming in arteries, leading to a heart attack ... measured the impact of diesel exhaust fumes on healthy volunteers ...
    ... interview with a researcher, please contact the Communications and External ... For more information on ORNL and its research and development ... you have a general media-related question or comment, you can ... Moving toward nanorobots . . . Nanoscale robots ...
    ... FALLS, Idaho,  July 13, 2011 International Isotopes ... nuclear medicine products, is pleased to announce it ... construction, technical, and management services firm, as the ... depleted uranium de-conversion facility in Lea County, New ...
    Cached Biology Technology:Diesel fumes pose risk to heart as well as lungs, study shows 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 3Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 4International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility 2International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility 3International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility 4
    (Date:9/17/2014)... Spanish researchers have obtained the first partial genome sequence ... pig found at the site of the Montsoriu Castle ... pig is closely related to today,s Iberian pig. Researchers ... with modern Iberian pigs. , The study, published in ... of pig species, and particularly on that of the ...
    (Date:9/17/2014)... 2014 Researchers at UTSouthwestern Medical Center have found ... apolipoprotein E, called apoE3, helps repair the lining of ... not get the benefit of this repair, putting them ... that we have identified one mechanism by which apoE3 ... variant, apoE4, is detrimental," said Dr. Philip Shaul ...
    (Date:9/17/2014)... been growing significantly faster since the 1960s. The typical ... but they have accelerated -- by as much as ... carried out by scientists from Technische Universitt Mnchen based ... been continuously observed since 1870. Their findings were published ... ago, "forest dieback" was a hot topic, with the ...
    Breaking Biology News(10 mins):Iberian pig genome remains unchanged after 5 centuries 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
    ... one day help physicians detect the very earliest stages ... , It would do so by improving the quality ... diagnostic tools used in doctors' offices ?the ultrasound machine. ... nano-sized particles injected into the animals improved the resulting ...
    ... have been infected with the H5N1 avian influenza virus, mostly ... virus does not spread easily from its pioneering human hosts ... a study of cells in the human respiratory tract reveals ... that makes it difficult for the virus to jump from ...
    ... Allergy and Infectious Diseases (NIAID), part of the National ... of anthrax toxin that worked well in small-scale animal ... of anthrax antitoxin is an important advance, not only ... but also because this technique could be used to ...
    Cached Biology News:Nanotechnology may find disease before it starts 2Nanotechnology may find disease before it starts 3Cell barrier shows why bird flu not so easily spread among humans 2Cell barrier shows why bird flu not so easily spread among humans 3Scientists design potent anthrax toxin inhibitor 2Scientists design potent anthrax toxin inhibitor 3